Can antiretroviral therapy prevent HIV-associated cognitive disorders?
- PMID: 24275675
- DOI: 10.1097/COH.0000000000000016
Can antiretroviral therapy prevent HIV-associated cognitive disorders?
Abstract
Purpose of review: In general, the initiation of combination antiretroviral (cART) is associated with improvement in cognitive function. However, the impact of cART has on cognitive function in neurologically asymptomatic HIV-infected individuals initiating therapy at high CD4 lymphocyte cell counts is unknown.
Recent findings: Cognitive function impairment remains prevalent despite effective cART. Several clinical risk factors for this condition have been described, including low nadir CD4 lymphocyte cell count which may be associated with greater neuroinflammatory process, a potential pathogenic mechanism underlying this cognitive impairment. The earlier initiation of antiretroviral therapy could theoretically avoid this risk factor and limit the degree of neuroinflammation. On the converse, the earlier initiation of cART may be associated with the development of neuronal toxicities.
Summary: This review article highlights the recent literature and arguments for and against the earlier initiation of cART with regards to cognitive function.
Similar articles
-
European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.J Antimicrob Chemother. 2013 Oct;68(10):2349-57. doi: 10.1093/jac/dkt206. Epub 2013 Jun 7. J Antimicrob Chemother. 2013. PMID: 23749950
-
Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.HIV Clin Trials. 2011 Nov-Dec;12(6):333-8. doi: 10.1310/hct1206-333. HIV Clin Trials. 2011. PMID: 22189152
-
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747. AIDS. 2013. PMID: 23719349
-
Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature.J Int Neuropsychol Soc. 2011 Nov;17(6):956-69. doi: 10.1017/S1355617711000968. Epub 2011 Aug 4. J Int Neuropsychol Soc. 2011. PMID: 21813033 Review.
-
Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?AIDS. 2015 Jan 28;29(3):253-61. doi: 10.1097/QAD.0000000000000538. AIDS. 2015. PMID: 25426811 Review.
Cited by
-
Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.Curr HIV/AIDS Rep. 2015 Mar;12(1):54-67. doi: 10.1007/s11904-014-0245-5. Curr HIV/AIDS Rep. 2015. PMID: 25604236 Free PMC article. Review.
-
Neuroinflammation: From Molecular Basis to Therapy.Int J Mol Sci. 2024 May 29;25(11):5973. doi: 10.3390/ijms25115973. Int J Mol Sci. 2024. PMID: 38892158 Free PMC article.
-
Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment.Retrovirology. 2018 Feb 1;15(1):17. doi: 10.1186/s12977-018-0400-y. Retrovirology. 2018. PMID: 29391069 Free PMC article.
-
CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders.Neurol Neuroimmunol Neuroinflamm. 2014 Oct 9;1(3):e36. doi: 10.1212/NXI.0000000000000036. eCollection 2014 Oct. Neurol Neuroimmunol Neuroinflamm. 2014. PMID: 25340088 Free PMC article.
-
Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis.Int J Nurs Sci. 2020 Mar 23;7(2):238-247. doi: 10.1016/j.ijnss.2020.03.007. eCollection 2020 Apr 10. Int J Nurs Sci. 2020. PMID: 32685622 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials